Workshop schedule as of 5.31.19 – sessions, times, and speakers are subject to change.
 |
| |
Time |
Event |
|
| |
8:30 – 9:00 AM |
Continental Breakfast |
|
| |
9:00 – 10:00 AM |
Challenges and Opportunities in Vaccine Manufacturing view abstract
Tarit Mukhopadhyay view bio
Associate Vice President, Vaccine Process Research & Development, Merck & Co., Inc. |
|
| |
10:00 – 11:00 AM |
Bioprocessing for Vaccine Viruses and Vectors view abstract
John Aunins view bio
Executive Vice President & Chief Technology Officer, Seres Therapeutics, Inc. |
|
| |
11:00 AM – 12:30 PM |
Influenza Vaccine Development and Manufacture view abstract
Matthew Downham view bio
Associate Director, AstraZeneca
|
|
| |
12:30 – 1:30 PM |
Lunch |
|
| |
1:30 – 2:30 PM |
Lessons from the MIT Consortium on Adventitious Agent Contamination in Biomanufacturing view abstract
Paul W. Barone view bio
Director, Consortium on Adventitious Agent Contamination in Biomanufacturing (CAACB), Center for Biomedical Innovation, Massachusetts Institute of Technology |
|
| |
2:30 – 3:30 PM |
Development of Capsular Polysaccharide Conjugate Vaccines view abstract
Steve A. Kolodziej view bio
Associate Research Fellow, Pfizer, Inc.
|
|
| |
3:30 – 4:00 PM |
Refreshment Break
|
|
| |
4:00 – 5:00 PM |
Quality Control of Human Viral Vaccines: Reducing the Risk of Viral and Microbial Contamination view abstract
Martin Wisher view bio
Senior Regulatory Consultant, Quality & Regulatory Management, MilliporeSigma
|
|
| |
5:00 – 6:00 PM |
Introduction to the Future Vaccine Manufacturing Research Hub (Vax-Hub) view abstract
Stefanie Frank view bio
Lecturer in Synthetic Biology; Modular Training for the Bioprocess Industries (MBI), Module Leader Vaccine Bioprocess Development and Commercialisation, University College London |
|
| |
6:30 – 7:30 PM |
Networking Reception |
|
|
|
